In a panel of melanoma cell lines, the most prevalent alterations were found in CDKN2A, including copy number loss, methylation, or mutation in this gene, which resulted in a decreased or absent CDKN2A protein and increased palbociclib sensitivity [135]. This evidence concerns the gene CDKN2A and melanoma.